Analyze Diet
Journal of veterinary pharmacology and therapeutics2006; 29(3); 165-171; doi: 10.1111/j.1365-2885.2006.00733.x

Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses.

Abstract: The pharmacokinetics of diltiazem were determined in eight healthy horses. Diltiazem HCl, 1 mg/kg i.v., was administered over 5 min. Venous blood samples were collected at regular intervals after administration. Plasma concentrations of diltiazem and desacetyldiltiazem were determined by high-performance liquid chromatography. A second, putative metabolite was detected, but could not be identified due to the lack of an authentic standard. Data were analyzed by nonlinear least-squares regression analysis. The median (minimum-maximum) peak plasma concentration of diltiazem was 727 (539-976) ng/mL. Plasma diltiazem concentration vs. time data were best described by a two-compartment model with first-order drug elimination. The distribution half-life was 12 (6-23) min, the terminal half-life was 93 (73-161) min, the mean residence time was 125 (99-206) min, total plasma clearance was 14.4 (10.4-18.6) mL/kg/min, and the volume of distribution at steady-state was 1.84 (1.46-2.51) L/kg. The normalized ratio of the area under the curve (AUC) of desacetyldiltiazem to the AUC of diltiazem was 0.088 (0.062-0.179). The disposition of diltiazem in horses was characterized by rapid distribution and elimination and a terminal half-life shorter than reported in humans and dogs. Because of the reported low pharmacologic activity, plasma diltiazem metabolite concentrations were not considered clinically important.
Publication Date: 2006-05-04 PubMed ID: 16669860DOI: 10.1111/j.1365-2885.2006.00733.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Clinical Trial
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research investigates how the drug diltiazem, commonly used in human and veterinary medicine as a calcium-channel blocker, is distributed and metabolized in horses after a single intravenous injection. Results show that diltiazem is rapidly distributed and eliminated in horses, with a quicker terminal half-life than in humans or dogs.

Methodology

  • The experiment was conducted on eight healthy horses.
  • Each horse received an intravenous dose of diltiazem HCl at a dose rate of 1mg/kg over a period of 5 minutes.
  • Blood samples were drawn at regular intervals following drug administration.

Results Collection

  • The plasma concentrations of diltiazem and desacetyldiltiazem (a metabolite of diltiazem) were measured using high-performance liquid chromatography.
  • A second unidentified metabolite was also detected, however, it was not identified because of a lack of a standard sample for comparison.
  • Data analysis was done using nonlinear least-squares regression analysis.

Findings

  • The median peak plasma concentration of diltiazem was 727 ng/mL.
  • The plasma diltiazem concentration vs. time data were best described by a two-compartment model with first-order drug elimination.
  • The distribution half-life was 12 minutes, the terminal half-life was 93 minutes, and the mean residence time was 125 minutes.
  • The total plasma clearance rate was calculated to be 14.4 mL/kg/min, and the volume of distribution at steady-state was determined to be 1.84 L/kg.
  • The normalized ratio of the area under the curve (AUC) of desacetyldiltiazem to the AUC of diltiazem was found to be 0.088.

Conclusions

  • The researchers concluded that diltiazem is quickly distributed and eliminated in horses, suggesting a shorter terminal half-life than what is reported in humans and dogs.
  • Due to the reported low pharmacologic activity of the diltiazem metabolites in the plasma, the researchers determined these concentrations are not clinically important.

Cite This Article

APA
Schwarzwald CC, Sams RA, Bonagura JD. (2006). Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses. J Vet Pharmacol Ther, 29(3), 165-171. https://doi.org/10.1111/j.1365-2885.2006.00733.x

Publication

ISSN: 0140-7783
NlmUniqueID: 7910920
Country: England
Language: English
Volume: 29
Issue: 3
Pages: 165-171

Researcher Affiliations

Schwarzwald, C C
  • Department of Veterinary Clinical Science, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210, USA. schwarzwald.4@osu.edu
Sams, R A
    Bonagura, J D

      MeSH Terms

      • Animals
      • Area Under Curve
      • Calcium Channel Blockers / administration & dosage
      • Calcium Channel Blockers / blood
      • Calcium Channel Blockers / pharmacokinetics
      • Diltiazem / administration & dosage
      • Diltiazem / blood
      • Diltiazem / pharmacokinetics
      • Drug Administration Schedule
      • Female
      • Horses / metabolism
      • Infusions, Intravenous / veterinary
      • Male

      Citations

      This article has been cited 0 times.